Registry tracking heart failure patients during acute episodes

Plain-English translation of NCT06726109 on ClinicalTrials.gov ↗ · Source last updated May 2025 · Translation generated June 2026 · How we translate trials

What is this trial?

This is a registry study that follows patients hospitalized for acute heart failure — a sudden worsening of the heart's ability to pump blood effectively. Doctors will treat you according to standard medical guidelines and their clinical judgment, and researchers will track your hospital care, treatments, and outcomes. The study is comparing how patients respond to vasodilator therapy (medications that relax and widen blood vessels) versus other treatment approaches.

Acute heart failure is a serious condition that sends many people to the hospital, but doctors don't have enough real-world data about which treatments work best for different patients in everyday practice. This study aims to fill that gap by carefully documenting how patients are actually treated and what happens to them.

Do you qualify?

You likely qualify if…

you have been admitted to the hospital within the past 24 hours for acute worsening of heart failure
you have signs of fluid overload (like swelling or shortness of breath) that require intravenous diuretic medications
your blood test shows elevated natriuretic peptide levels, confirming acute heart failure
your heart ultrasound shows an enlarged left ventricle or moderate leakage through your mitral valve
your heart ultrasound confirms your heart's pumping function is reduced (ejection fraction below 40%)

You likely don't qualify if…

you are in cardiogenic shock, meaning your blood pressure has dropped dangerously and your organs aren't getting enough blood
you have severe kidney disease or are already on dialysis
you have end-stage liver disease
you are already receiving inotropes or vasopressors (strong heart-supporting medications), or have received certain other medications within the past month
your heart failure was caused by a recent heart attack, myocarditis, severe heart valve disease, or other structural problems requiring different care

What participation looks like

You will receive standard medical care for your acute heart failure hospitalization as your doctors see fit, guided by current clinical guidelines. Researchers will observe your treatment course, collect information from your medical records (including ultrasound results and blood tests), and track what medications you receive and how you respond. You will not be randomly assigned to a specific treatment — your doctor will decide your care — but the study will compare outcomes between patients who receive vasodilator therapy and those who don't.

AI-generated summary from trial data · Jun 28, 2026 · Not medical advice

Trial locations(4 sites)

Belgium

division of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium. Hasselt University, Belgium., Genk, Belgium

Italy

Rivoli Hospital, Rivoli, Italy

San Giovanni Bosco Hospital, Turin, Italy

Santa Maria della Misericordia, Azienda sanitaria universitaria Friuli Centrale,, Udine, Italy

Key details

Sponsor

ASL Città di Torino

Collaborators

Hospital of Rivoli, Ziekenhuis Oost-Limburg

Enrollment target

~600 participants

Started

April 2025

Primary completion

April 2030

Last updated on clinicaltrials.gov in May 2025.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Maurizio Bertaina, MD

Division of Cardiology, San Giovanni Bosco,ASL Città di Torino, Turin, Italy

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

View full record on ClinicalTrials.gov